ADAR1 Capital Management »

Bicycle Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Bicycle Therapeutics (BCYC) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Bicycle Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Bicycle Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bicycle Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.3M 129k 18.08

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Bicycle Therapeutics

Paradigm Biocapital Advisors
Leucadia National Corporation
Baker Bros. Advisors
First Light Asset Management
Westfield Capital Management Company
Candriam Luxembourg S.C.A.
Bnp Paribas Investment Partners
Ridgeback Capital Investments
RA Capital Management
Bank of America Corporation
Kennedy Capital Management
Nomura Holdings
Citadel Advisors
T. Rowe Price Associates
Millennium Management

View all funds holding Bicycle Therapeutics